{
  "id": 6598782,
  "title": "Top 10 Contract Development and Manufacturing Organizations 2026",
  "url": "https://urgent.news/2026/09/10/top-10-contract-development-and-manufacturing-organizations-2026",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-10T14:22:27.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/"
  },
  "original_language": "en",
  "account": "The top Contract Development and Manufacturing Organizations (CDMOs) continue to thrive despite rising costs associated with their services, according to a survey of over 300 biopharma leaders published in August by McKinsey. While batch processing prices have increased since the pandemic and further increases are expected, biopharma leaders remain confident that their demand for outsourced services will continue to expand, particularly for services that prioritize speed, flexibility, and specialized capabilities.\n\nThe global CDMO market is projected to grow by 6.4% in 2025, from $173.7 billion to $184.9 billion, and reach $342 billion by 2035, with a compound annual growth rate of 7.1%. The survey also revealed that biopharma customers are increasingly focusing on reliability, execution, and cost competitiveness, as quality is now considered a baseline requirement rather than a differentiator. Quality issues can account for 15-20% of the cost of goods sold, while the FDA has increased Form 483 violation reports by 33% compared to pre-COVID-19 levels, with remediation plans costing anywhere from $10 million to $50 million.\n\nThe survey identified three key factors driving CDMO decisions among customers: growing pressure to improve operational performance and productivity, rising cost sensitivity among customers, and thin loyalty to CDMOs. This suggests that many CDMOs are struggling to bridge the gap between physical capacity and baseline execution, while also needing to achieve productivity needed for competitive pricing.\n\nThe updated A-List of Top 10 CDMOs, ranked by 2025 revenues, shows that eight of the top 10 CDMOs have recorded year-over-year revenue increases. The combined revenue of the top 10 CDMOs grew to $35.116 billion in 2025, up six percent from $33.127 billion in 2024. The list now excludes Catalent due to its acquisition by Novo Holdings for $16.5 billion in 2024.",
  "summary": "A majority of biopharmas are expected to increase their reliance on CDMOs in coming years despite rising costs for their services. The post Top 10 Contract Development and Manufacturing Organizations 2026 appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}